

Xin Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8937379/publications.pdf>

Version: 2024-02-01

46
papers

6,814
citations

186265
28
h-index

223800
46
g-index

46
all docs

46
docs citations

46
times ranked

3569
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis. <i>Autophagy</i> , 2023, 19, 54-74.	9.1	44
2	Cuproptosis: a copper-triggered modality of mitochondrial cell death. <i>Cell Research</i> , 2022, 32, 417-418.	12.0	346
3	Regulation and function of autophagy in pancreatic cancer. <i>Autophagy</i> , 2021, 17, 3275-3296.	9.1	89
4	Ferroptosis: machinery and regulation. <i>Autophagy</i> , 2021, 17, 2054-2081.	9.1	765
5	Ferroptosis: molecular mechanisms and health implications. <i>Cell Research</i> , 2021, 31, 107-125.	12.0	1,406
6	Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. <i>Seminars in Cancer Biology</i> , 2021, 68, 105-122.	9.6	27
7	Broadening horizons: the role of ferroptosis in cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 280-296.	27.6	1,216
8	Tumor heterogeneity in autophagy-dependent ferroptosis. <i>Autophagy</i> , 2021, 17, 3361-3374.	9.1	116
9	Characteristics and Biomarkers of Ferroptosis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 637162.	3.7	199
10	PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. <i>Cell Reports</i> , 2021, 34, 108767.	6.4	112
11	Ferroptosis by Lipid Peroxidation: The Tip of the Iceberg?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 646890.	3.7	19
12	Targeting Ubiquitin-Proteasome System With Copper Complexes for Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 649151.	3.5	24
13	The dual role of ferroptosis in pancreatic cancer: a narrative review. <i>Journal of Pancreatology</i> , 2021, 4, 76-81.	0.9	6
14	Ferroptosis in infection, inflammation, and immunity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	298
15	Cullin 2-RBX1 E3 ligase and USP2 regulate antithrombin ubiquitination and stability. <i>FASEB Journal</i> , 2021, 35, e21800.	0.5	3
16	Cell death in pancreatic cancer: from pathogenesis to therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 804-823.	17.8	156
17	Pathological Significance and Prognostic Roles of Indirect Bilirubin/Albumin Ratio in Hepatic Encephalopathy. <i>Frontiers in Medicine</i> , 2021, 8, 706407.	2.6	4
18	Organelle-specific regulation of ferroptosis. <i>Cell Death and Differentiation</i> , 2021, 28, 2843-2856.	11.2	138

#	ARTICLE	IF	CITATIONS
19	Regulation of Bax-dependent apoptosis by mitochondrial deubiquitinase USP30. <i>Cell Death Discovery</i> , 2021, 7, 211.	4.7	8
20	Targeting ferroptosis in pancreatic cancer: a double-edged sword. <i>Trends in Cancer</i> , 2021, 7, 891-901.	7.4	78
21	Cellular degradation systems in ferroptosis. <i>Cell Death and Differentiation</i> , 2021, 28, 1135-1148.	11.2	283
22	The role of ferroptosis in lung cancer. <i>Biomarker Research</i> , 2021, 9, 82.	6.8	41
23	Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment. <i>Acta Pharmacologica Sinica</i> , 2021, , .	6.1	1
24	Iron Metabolism in Ferroptosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 590226.	3.7	408
25	Transcription factors in ferroptotic cell death. <i>Cancer Gene Therapy</i> , 2020, 27, 645-656.	4.6	141
26	Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 949.	2.8	60
27	Autophagy Induced by Proteasomal DUB Inhibitor NiPT Restricts NiPT-Mediated Cancer Cell Death. <i>Frontiers in Oncology</i> , 2020, 10, 348.	2.8	8
28	Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase. <i>BioMetals</i> , 2018, 31, 29-43.	4.1	9
29	Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 780-797.	1.6	20
30	Bilirubin neurotoxicity is associated with proteasome inhibition. <i>Cell Death and Disease</i> , 2017, 8, e2877-e2877.	6.3	28
31	Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 655-668.	5.9	40
32	Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells. <i>European Journal of Pharmacology</i> , 2017, 815, 147-155.	3.5	39
33	Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation. <i>Cell Death and Disease</i> , 2017, 8, e2913-e2913.	6.3	20
34	Repurposing an antidiarrheal agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. <i>Oncotarget</i> , 2017, 8, 13942-13956.	1.8	25
35	Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. <i>Biochemical Pharmacology</i> , 2016, 116, 22-38.	4.4	33
36	A microRNA-mediated decrease in eukaryotic initiation factor 2 β promotes cell survival during PS-341 treatment. <i>Scientific Reports</i> , 2016, 6, 21565.	3.3	23

#	ARTICLE	IF	CITATIONS
37	Nickel pyrrhione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. <i>Journal of Hematology and Oncology</i> , 2016, 9, 129.	17.0	19
38	A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. <i>Oncogene</i> , 2016, 35, 5916-5927.	5.9	52
39	Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 2796-2808.	1.8	57
40	Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. <i>Scientific Reports</i> , 2015, 5, 9694.	3.3	21
41	Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells. <i>Cancer Cell & Microenvironment</i> , 2015, 1, .	0.8	8
42	Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation. <i>Clinical Cancer Research</i> , 2014, 20, 151-163.	7.0	116
43	Anacardic acid induces cell apoptosis associated with induction of ATF4-dependent endoplasmic reticulum stress. <i>Toxicology Letters</i> , 2014, 228, 170-178.	0.8	38
44	A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. <i>Scientific Reports</i> , 2014, 4, 5240.	3.3	60
45	Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. <i>Oncotarget</i> , 2014, 5, 5453-5471.	1.8	139
46	Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. <i>Oncotarget</i> , 2014, 5, 9118-9132.	1.8	71